Skip to main content
SpringerLink
Log in

Vaccines in Rheumatic Diseases

  • Chapter
  • First Online:
Infections and the Rheumatic Diseases

  • 765 Accesses

Abstract

Vaccination is one of the most important public health strategies to prevent infectious diseases, reduce their severity, or prevent the complications thereof, thus decreasing morbidity and mortality in vulnerable groups such as patients with autoimmune inflammatory rheumatic diseases (AIRD).

Patients with AIRD entertain an increased risk of acquiring infections, as well as an increase in the morbidity and mortality associated with these infections, by immunosuppression due to their underlying condition, their comorbidities, and the immunosuppressive treatment. In addition to this, the immunomodulatory medications can modify the effectiveness of vaccines; therefore, it is important that the rheumatologist not only understand the efficacy and safety of each vaccine but also the appropriate time for their prescription.

This chapter focuses on the indications, contraindications, and efficacy of the vaccines included in the adult vaccination schedules of patients with AIRD, as well as special considerations such as schemes for patients traveling abroad.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

ACR:

American College of Rheumatology

AIRD:

Autoimmune inflammatory rheumatic diseases

Anti-HBs ab:

Antibodies against the HBV surface antigens

BCG:

Bacillus Calmette-Guérin

CDC:

Centers for Disease Control and Prevention

CI:

Confidence interval

COMORA:

Comorbidities in rheumatoid arthritis

CS:

Corticosteroids

DMARDs:

Disease-modifying anti-rheumatic drugs

DTaP:

Diphtheria, tetanus, and pertussis vaccine

EULAR:

European League Against Rheumatism

HBV:

Hepatitis B virus

Hib:

Haemophilus influenzae type b

HIV:

Human immunodeficiency virus

HPV:

Human papillomavirus

IDSA:

Infectious Diseases Society of America

IPD:

Invasive pneumococcal disease

(MenACWY):

Polysaccharide and conjugate against serogroups A, C, W, and Y meningococcal vaccine

MenB:

Recombinant vaccine against serogroup B of meningococcus

MMR:

Measles, mumps, and rubella vaccine

MTX:

Methotrexate

PCV13:

13-Valent pneumococcal conjugate vaccine

PPV23:

23-Valent polysaccharide vaccine

RA:

Rheumatoid arthritis

RR:

Relative risk

RZV:

Recombinant zoster vaccine

SLE:

Systemic lupus erythematous

SS:

Systemic sclerosis

TB:

Tuberculosis

Td:

Tetanus/diphtheria

TNFi:

Tumoral necrosis factor inhibitors

UK:

United Kingdom

VZV:

Varicella zoster virus

YEL-AND:

Yellow fever vaccine-associated neurologic disease

YEL-AVD:

Yellow fever vaccine-associated viscerotropic disease

ZVL:

Zoster vaccine live

References

  1. Papadopoulou D, Tsoulas C, Tragiannidis A, Sipsas NV. Role of vaccinations and prophylaxis in rheumatic diseases. Best Pract Res Clin Rheumatol [Internet]. 2015;29(2):306–18. Available from: https://doi.org/10.1016/j.berh.2015.02.001.

    Article  Google Scholar 

  2. Meroni PL, Zavaglia D, Girmenia C. Vaccinations in adults with rheumatoid arthritis in an era of new disease-modifying anti-rheumatic drugs. Clin Exp Rheumatol. 2018;36(2):317–28.

    PubMed  Google Scholar 

  3. Van Assen S, Elkayam O, Agmon-levin N, Cervera R, Doran MF, Dougados M, et al. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-im. Autoimmun Rev [Internet]. 2011;10(6):341–52. Available from: https://doi.org/10.1016/j.autrev.2010.12.003.

    Article  CAS  Google Scholar 

  4. Ada G. Overview of vaccines and vaccination. Mol Biotechnol. 2005;29(3):255–71.

    Article  CAS  Google Scholar 

  5. Mackay IR, Rosen FS. Vaccines and vaccination. N Engl J Med. 2001;345(14):1042–53.

    Article  Google Scholar 

  6. Siegrist C-A. Vaccine immunology. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines [Internet]: Sixt. W.B. Saunders; 2013. p. 14–32. Available from: http://linkinghub.elsevier.com/retrieve/pii/B9781455700905000045.

  7. Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016;68(1):1–25.

    Article  Google Scholar 

  8. Wong PKK, Bagga H, Hanrahan P. A practical approach to vaccination of patients with autoimmune inflammatory rheumatic diseases in Australia. Intern Med J. 2017;47(5):491–500.

    Article  Google Scholar 

  9. Perry LM, Winthrop KL, Curtis JR. Vaccinations for rheumatoid arthritis. Curr Rheumatol Rep. 2014;16(8):431.

    Article  Google Scholar 

  10. Cordeiro I, Duarte A, Ferreira J, Goncalves M, Meirinhos T, Rocha T, et al. Recommendations for vaccination in adult patients with systemic inflammatory rheumatic diseases from the Portuguese Society of Rheumatology. Acta Reumatol Port. 2016;41:112–30.

    CAS  PubMed  Google Scholar 

  11. Van Assen S, Elkayam O, Cervera R, Doran MF, Dougados M, Emery P, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011;70:414–22.

    Article  Google Scholar 

  12. Brenol CV, Azevedo VF, Bonvehi PE, Coral-Alvarado PX, Granados J, Muñoz-Louis R, et al. Vaccination recommendations for adults with autoimmune inflammatory rheumatic diseases in Latin America. J Clin Rheumatol. 2018;24(3):138–47.

    PubMed  Google Scholar 

  13. Westra J, Rondaan C, Van Assen S, Bijl M. Vaccination of patients with autoimmune inflammatory rheumatic diseases. Nat Rev Rheumatol [Internet]. 2015;11(3):135–45. Available from: https://doi.org/10.1038/nrrheum.2014.206.

    Article  Google Scholar 

  14. Müller-Ladner C, Müller-Ladner U. Vaccination and inflammatory arthritis: overview of current vaccines and recommended uses in rheumatology topical collection on infections and arthritis. Curr Rheumatol Rep. 2013;15(6):330.

    Article  Google Scholar 

  15. Friedman MA, Winthrop K. Vaccinations for rheumatoid arthritis. Curr Opin Rheumatol. 2016;28(3):330–6.

    Article  CAS  Google Scholar 

  16. Huang Y, Wang H, Wan L, Lu X, Tam WWS. Is systemic lupus erythematosus associated with a declined immunogenicity and poor safety of influenza vaccination? A systematic review and meta-analysis. Medicine (United States). 2016;95(19):1–7.

    Google Scholar 

  17. Milanovic M, Stojanovich L, Djokovic A, Kontic M, Gvozdenovic E. Influenza vaccination in autoimmune rheumatic disease patients. Tohoku J Exp Med. 2013;229(1):29–34.

    Article  CAS  Google Scholar 

  18. Elkayam O, Amir S, Mendelson E, Schwaber M, Grotto I, Wollman J, et al. Efficacy and safety of vaccination against pandemic 2009 influenza a (H1N1) virus among patients with rheumatic diseases. Arthritis Care Res. 2011;63(7):1062–7.

    Article  Google Scholar 

  19. Saad CGS, Borba EF, Aikawa NE, Silva CA, Pereira RMR, Calich AL, et al. Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases. Ann Rheum Dis. 2011;70(6):1068–73.

    Article  Google Scholar 

  20. Kubota T, Nii T, Nanki T, Kohsaka H, Harigai M, Komano Y, et al. Anti-tumor necrosis factor therapy does not diminish the immune response to influenza vaccine in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2007;17(6):531–3.

    Article  Google Scholar 

  21. Kapetanovic MC, Saxne T, Nilsson J-A, Geborek P. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology [Internet]. 2006;46(4):608–11. Available from: https://academic.oup.com/rheumatology/article-lookup/doi/10.1093/rheumatology/kel366.

    Article  Google Scholar 

  22. Elkayam O, Bashkin A, Mandelboim M, Litinsky I, Comaheshter D, Levartovsky D, et al. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum [Internet]. 2010;39(6):442–7. Available from: https://doi.org/10.1016/j.semarthrit.2008.12.002.

    Article  CAS  Google Scholar 

  23. Van Assen S, Holvast A, Benne CA, Posthumus MD, Van Leeuwen MA, Voskuyl AE, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum. 2010;62(1):75–81.

    Article  Google Scholar 

  24. Fomin I, Caspi D, Levy V, Varsano N, Shalev Y, Paran D, et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNFα blockers. Ann Rheum Dis. 2006;65(2):191–4.

    Article  CAS  Google Scholar 

  25. Agmon-Levin N, Kivity S, Shoenfeld Y. Influenza vaccine and autoimmunity. Isr Med Assoc J. 2009;11(3):183–5.

    PubMed  Google Scholar 

  26. Abu-Shakra M, Press J, Buskila D, Sukenik S. Influenza vaccination of patients with systemic lupus erythematosus: safety and immunogenecity issues. Autoimmun Rev. 2007;6(8):543–6.

    Article  Google Scholar 

  27. Müller RB, Maier R, Hoschler K, Zambon M, Ludewig B, Herrmann M, et al. Efficient boosting of the antiviral T cell response in B cell-depleted patients with autoimmune rheumatic diseases following influenza vaccination. Clin Exp Rheumatol. 2013;31(5):723–30.

    PubMed  Google Scholar 

  28. Holvast A, van Assen S, de Haan A, Huckriede A, Benne CA, Westra J, et al. Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: an open, prospective, controlled study. Rheumatology. 2009;48(10):1294–9.

    Article  Google Scholar 

  29. Hmamouchi I, Winthrop K, Launay O, Dougados M. Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis: data from the international COMORA cohort. Vaccine [Internet]. 2015;33(12):1446–52. Available from: https://doi.org/10.1016/j.vaccine.2015.01.065.

    Article  Google Scholar 

  30. Shelton CM, Gray MD, Crill CM. To mist or not to mist: an update on the recommendations for live-attenuated influenza vaccine. J Am Pharm Assoc [Internet]. 2018;58(4):457–9. Available from: https://doi.org/10.1016/j.japh.2018.06.005.

    Article  Google Scholar 

  31. Weycker D, Farkouh RA, Strutton DR, Edelsberg J, Shea KM, Pelton SI. Rates and costs of invasive pneumococcal disease and pneumonia in persons with underlying medical conditions. BMC Health Serv Res [Internet]. 2016;16(1):1–10. Available from: https://doi.org/10.1186/s12913-016-1432-4.

  32. Bahuaud M, Beaudouin-Bazire C, Husson M, Molto A, Launay O, Batteux F, et al. Immunogenicity and persistence of a prime-boost re-vaccination strategy for pneumococcal vaccines in patients with rheumatoid arthritis. Hum Vaccin Immunother. 2018;14(6):1464–70.

    Article  Google Scholar 

  33. Elkayam O, Caspi D, Reitblatt T, Charboneau D, Rubins JB. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum. 2004;33(4):283–8.

    Article  CAS  Google Scholar 

  34. Thomas K, Vassilopoulos D. Immunization in patients with inflammatory rheumatic diseases. Best Pract Res Clin Rheumatol [Internet]. 2016;30(5):946–63. Available from: https://doi.org/10.1016/j.berh.2016.10.009.

    Article  Google Scholar 

  35. Broyde A, Arad U, Madar-Balakirski N, Paran D, Kaufman I, Levartovsky D, et al. Longterm efficacy of an antipneumococcal polysaccharide vaccine among patients with autoimmune inflammatory rheumatic diseases. J Rheumatol. 2016;43(2):267–72.

    Article  CAS  Google Scholar 

  36. Hua C, Barnetche T, Combe B, Morel J. Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) [Internet]. 2014;66(7):1016–26. Available from: http://doi.wiley.com/10.1002/acr.22246.

    Article  CAS  Google Scholar 

  37. Migita K, Akeda Y, Akazawa M, Tohma S, Hirano F, Ideguchi H, et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus. Arthritis Res Ther [Internet]. 2015;17(1):149. Available from: http://arthritis-research.com/content/17/1/149.

    Article  Google Scholar 

  38. Migita K, Akeda Y, Akazawa M, Tohma S, Hirano F, Ideguchi H, et al. Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients. Arthritis Res Ther [Internet]. 2015;17(1):1–10. Available from: https://doi.org/10.1186/s13075-015-0863-3.

  39. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546–55.

    Article  Google Scholar 

  40. Moghoofei M, Mostafaei S, Ashraf-Ganjouei A, Kavosi H, Mahmoudi M. HBV reactivation in rheumatic diseases patients under therapy: a meta-analysis. Microb Pathog [Internet]. 2018;114:436–43. Available from: https://doi.org/10.1016/j.micpath.2017.12.014.

    Article  CAS  Google Scholar 

  41. Sebastiani M, Atzeni F, Milazzo L, Quartuccio L, Scirè C, Gaeta GB, et al. Italian consensus guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis. Joint Bone Spine [Internet]. 2017;84(5):525–30. Available from: https://doi.org/10.1016/j.jbspin.2017.05.013.

    Article  Google Scholar 

  42. Centers for Diseace Control and Prevention. Hepatitis B. Epidemiol Prev Vaccine-Prev Dis. 2015;(November):149–74.

    Google Scholar 

  43. Bijl M, Agmon-Levin N, Dayer JM, Israeli E, Gatto M, Shoenfeld Y. Vaccination of patients with auto-immune inflammatory rheumatic diseases requires careful benefit-risk assessment. Autoimmun Rev [Internet]. 2012;11(8):572–6. Available from: https://doi.org/10.1016/j.autrev.2011.10.015.

    Article  CAS  Google Scholar 

  44. Elkayam O, Yaron M, Caspi D. Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. Ann Rheum Dis. 2002;61(7):623–5.

    Article  CAS  Google Scholar 

  45. Nelson NP. Hepatitis A. In: Brunette GW, editor. CDC yellow book. New York: Oxford University Press; 2018.

    Google Scholar 

  46. Rosdahl A, Herzog C, Frösner G, Norén T, Rombo L, Askling HH. An extra priming dose of hepatitis A vaccine to adult patients with rheumatoid arthritis and drug induced immunosuppression – a prospective, open-label, multi-center study. Travel Med Infect Dis [Internet]. 2018;21(August):43–50. Available from: https://doi.org/10.1016/j.tmaid.2017.12.004.

    Article  Google Scholar 

  47. Bühler S, Visser LG. Hepatitis A vaccination in patients with rheumatic diseases and drug-induced immunosuppression. Travel Med Infect Dis. 2014;12(2):115–7.

    Article  Google Scholar 

  48. Askling HH, Rombo L, Van Vollenhoven R, Hallén I, Thörner Å, Nordin M, et al. Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis: a prospective, open-label, multi-centre study. Travel Med Infect Dis. 2014;12(2):134–42.

    Article  Google Scholar 

  49. Mok CC. Herpes zoster vaccination in systemic lupus erythematosus: the current status. Hum Vaccin Immunother [Internet]. 2019;15(1):45–8. Available from: https://www.tandfonline.com/doi/full/10.1080/21645515.2018.1514228.

    Article  Google Scholar 

  50. Wong KK, Burdette E, Mahon BE, Mintz ED, Ryan ET, Reingold AL. Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccine. MMWR Morb Mortal Wkly Rep [Internet]. 2017;66(18):482–5. Available from: http://www.cdc.gov/mmwr/volumes/66/wr/mm6618a6.htm.

    Article  Google Scholar 

  51. Grein IHR, Groot N, Lacerda MI, Wulffraat N, Pileggi G. HPV infection and vaccination in systemic lupus erythematosus patients: what we really should know. Pediatr Rheumatol [Internet]. 2016;14(1):10–7. Available from: https://doi.org/10.1186/s12969-016-0072-x.

  52. Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep [Internet]. 2014;63(RR-05):1–30. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25167164.

    Google Scholar 

  53. Arbyn M, Xu L, Simoens C, Martin-Hirsch PPL. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018;2018(5):1–241.

    Google Scholar 

  54. Castellsagué X, Muñoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age. Br J Cancer. 2011;105(1):28–37.

    Article  Google Scholar 

  55. Muñoz N, Manalastas R, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. Lancet. 2009;373(9679):1949–57.

    Article  Google Scholar 

  56. Kim SC, Feldman S, Moscicki A-B. Risk of human papillomavirus infection in women with rheumatic disease: cervical cancer screening and prevention. Rheumatology [Internet]. 2018;57(suppl_5):v26–33. Available from: https://academic.oup.com/rheumatology/article/57/suppl_5/v26/5076149.

    Article  CAS  Google Scholar 

  57. Gatto M, Agmon-Levin N, Soriano A, Manna R, Maoz-Segal R, Kivity S, et al. Human papillomavirus vaccine and systemic lupus erythematosus. Clin Rheumatol. 2013;32(9):1301–7.

    Article  Google Scholar 

  58. Martínez-Lavín M. HPV vaccination syndrome: a clinical mirage, or a new tragic fibromyalgia model. Reumatol Clin [Internet]. 2018;14(4):211–4. Available from: https://doi.org/10.1016/j.reuma.2018.01.014.

    Article  Google Scholar 

  59. Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination — updated recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep [Internet]. 2016;65(49):1405–8. Available from: http://www.cdc.gov/mmwr/volumes/65/wr/mm6549a5.htm.

    Article  Google Scholar 

  60. Petrosky E, Bocchini JA, Hariri S, Cheesson H, Curtis CR, Saraiya M, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep [Internet]. 2015;64(11):300–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25811677.

    Google Scholar 

  61. Centers for Disease Control and Prevention. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(4):1–34.

    Google Scholar 

  62. Liang J, Tiwari T, Moro P, Messonnier M, Reingold A, Sawyer M, et al. Prevention of pertussis, tetanus, and diphtheria with vaccines in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2018;67(2):1–44.

    PubMed  PubMed Central  Google Scholar 

  63. Kim DK, Riley LE, Hunter P, Bridges CB, Woods LD, Wilson A, et al. Recommended immunization schedule for adults aged 19 years or older, United States, 2018. Ann Intern Med. 2018;168(3):210–20.

    Article  Google Scholar 

  64. Briere EC, Rubin L, Moro PL, Cohn A, Clark T, Messonnier N. Prevention and control of haemophilus influenzae type b disease: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep [Internet]. 2014;63(RR-01):1–14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24572654.

    Google Scholar 

  65. Jean K, Donnelly CA, Ferguson NM, Garske T. A meta-analysis of serological response associated with yellow fever vaccination. Am J Trop Med Hyg. 2016;95(6):1435–9.

    Article  CAS  Google Scholar 

  66. Centers for Disease Control and Prevention. In: Brunette GW, editor. CDC yellow book health information for international travel [Internet]. New York: Oxford University Press; 2017. Available from: https://wwwnc.cdc.gov/travel/yellowbook/2018/table-of-contents.

    Google Scholar 

  67. Saavedra M, Riera L, Bottale A, Mariani M, Maiza A, Ambrosio A. Estabilidad de la vacuna Candid #1 para prevenir la fiebre hemorrágica argentina. Medicina (B Aires). 2017;77:353–7.

    Google Scholar 

  68. Pavlakis GN, Felber BK. A new step towards an HIV/AIDS vaccine. Lancet [Internet]. 2018;6736(18):10–1. Available from: https://doi.org/10.1016/S0140-6736(18)31548-4.

    Article  Google Scholar 

  69. Lévy Y, Lane C, Piot P, Beavogui AH, Kieh M, Leigh B, et al. Prevention of Ebola virus disease through vaccination: where we are in 2018. Lancet [Internet]. 2018;392(10149):787–90. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673618317100.

    Article  Google Scholar 

  70. The Lancet Infectious Diseases. The dengue vaccine dilemma. Lancet Infect Dis [Internet]. 2018;18(2):123. Available from: https://doi.org/10.1016/S1473-3099(18)30023-9.

    Article  CAS  Google Scholar 

  71. Giel-Moloney M, Goncalvez AP, Catalan J, Lecouturier V, Girerd-Chambaz Y, Diaz F, et al. Chimeric yellow fever 17D-Zika virus (ChimeriVax-Zika) as a live-attenuated Zika virus vaccine. Sci Rep [Internet]. 2018;8(1):13206. Available from: http://www.nature.com/articles/s41598-018-31375-9.

    Article  Google Scholar 

  72. Touret F, Gilles M, Klitting R, Aubry F, de Lamballerie X, Nougairede A. Live Zika virus chimeric vaccine candidate based on a yellow fever 17-D attenuated backbone. bioRxiv [Internet]. 2018:272625. Available from: https://www.biorxiv.org/content/early/2018/02/27/272625.

  73. Nami S, Mohammadi R, Vakili M, Khezripour K, Mirzaei H, Morovati H. Fungal vaccines, mechanism of actions and immunology: a comprehensive review. Biomed Pharmacother [Internet]. 2019;109(October 2018):333–44. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0753332218353903.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Musculoskeletal and Rheumatic Disorders, Instituto Nacional de Rehabilitacion Luis Guillermo Ibarra Ibarra, Mexico City, Mexico

    Carlos Pineda & Carina Soto-Fajardo

  2. Immunogenetics Division, Department of Transplants, Instituto Nacional de Ciencias Medica y Nutricion Salvador Zubirán, Mexico City, Mexico

    Julio Granados

Authors
  1. Carlos Pineda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carina Soto-Fajardo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Julio Granados
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. LSU Health Sciences at New Orleans, Louisiana State University, New Orleans, LA, USA

    Luis R. Espinoza

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Pineda, C., Soto-Fajardo, C., Granados, J. (2019). Vaccines in Rheumatic Diseases. In: Espinoza, L. (eds) Infections and the Rheumatic Diseases. Springer, Cham. https://doi.org/10.1007/978-3-030-23311-2_39

Download citation

Publish with us

Policies and ethics

Search

Navigation